Please assess the completion status of the following clinical trial:

Trial Title: Endostar Combined With MPFC Adjuvant Treatment of Esophageal Cancer Clinical Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* patients with esophageal cancer confirmed by histology or cytology;~* according to TNM staging for Ⅲ period, previous untreated can be removed and potentially resectable esophageal cancer patients;~* can eat more than liquid diet;No signs before esophageal perforation;No distant metastasis;~* male or female, age 18 and 75 years old or less or more;~* ECOG PS 0 \~ 1 minute;~* is expected to survive period for 3 months or more,~* enough blood function: absolute neutrophil count (ANC) or 2 x 109 / L and the • platelet count 100 x 109 / L or higher acuity 9 g/dL and hemoglobin;Liver function~* enough: upper limit of total bilirubin acuities were normal (ULN);AST and ALT acuities were 2.5 times the upper limit of normal (ULN);Alkaline phosphatase 5 times the upper limit of normal or less (ULN);~* enough renal function, serum creatinine or less normal limit (ULN) or calculated creatinine clearance or 60 mL/min.~* basic normal ecg, no healing trauma;~* always not received anti-tumor drug treatment;~* ever had had surgery patients, request to study treatment began to have more than 4 weeks, and the patient has recovered;~* a complete uterus of female in the group within 28 days before the study must have a negative pregnancy test results (except amenorrhea has 24 months).If the pregnancy test from the first time for more than 7 days, is the need for urine pregnancy test validation (within 7 days before the first delivery).~* prior to biological agents, especially e. coli genetically engineered products without severe allergic reactions;~Exclusion Criteria:~* there is a clear taxol allergy history;~* pregnancy, nursing mothers, or have fertility but not women using contraception;~* the existing serious acute infection, and not be controlled;Or fester sex and chronic infection, wound in delay no more;~* the original serious heart disease, including: higher risk of congestive heart failure, unable to control arrhythmia, unstable angina, myocardial infarction, severe valvular heart disease, and resistant hypertension;~* is not easy to control nerve, mental illness or mental disorders, compliance is poor, can't cooperate with accounts and response to treatment;Primary brain tumors or CNS metastases illness did not get a control, has obvious symptoms in cranial hypertension or nerve spirit;~* with bleeding tendency;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Endostar combined with MPFC (Type: EXPERIMENTAL): Chemotherapy regimens (er degree + mPFC) :~Endostar:~degrees 30 mg civ24h d0-6;~Liposo:~135 mg/m2 D1; cisplatin: D1-3, 25 mg/m2~Gimeracil and Oteracil Potassium (Tegafur):~(40 mg bid Tegafur), D1-14. A course of 3 weeks, after two course of chemotherapy the CT/MR/ultrasonic gastroscopy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues